Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Recorded changes
86,510 on record
Recorded policy changes, newest first| Recorded | Payer | Policy | Change |
|---|
| May 14, 2026 | HealthPartners | Gaucher disease enzyme replacement therapy: imiglucerase (Cerezyme), velaglucerase (Vpriv), and taliglucerase (Elelyso)PayerPolicy · HEALTHPARTNERS-CC-AENTRY-046263 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | TransplantsPayerPolicy · HEALTHPARTNERS-CC-AENTRY-046180 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Transcutaneous electrical nerve stimulator (TENS) unitPayerPolicy · HEALTHPARTNERS-CC-AENTRY-046242 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Transcranial magnetic stimulationPayerPolicy · HEALTHPARTNERS-CC-AENTRY-046125 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Tofersen (Qalsody)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-265592 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Tisotumab vedotin (Tivdak) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-247637 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Teprotumumab-trbw (Tepezza) and veligrotug-vvze (Lumvoa) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-231638 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Teprotumumab-trbw (Tepezza) and veligrotug-vvze (Lumvoa)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-226990 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Temporomandibular disorder (TMD) treatments – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-266175 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Temporomandibular disorder (TMD) treatmentsPayerPolicy · HEALTHPARTNERS-CC-AENTRY-046169 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Sutimlimab-jome (Enjaymo)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-249186 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Surgical treatments for lipedema and lymphedemaPayerPolicy · HEALTHPARTNERS-CC-ENTRY-247567 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Statin medications for prevention of cardiovascular diseasePayerPolicy · HEALTHPARTNERS-CC-ENTRY-194065 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Spinal decompression surgeriesPayerPolicy · HEALTHPARTNERS-CC-ENTRY-256055 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Spesolimab-sbzo (Spevigo)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-254279 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Specialty testing: orthopedicsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-247314 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Specialty testing: ophthalmologyPayerPolicy · HEALTHPARTNERS-CC-ENTRY-232487 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Specialty testing: nutrition and metabolismPayerPolicy · HEALTHPARTNERS-CC-ENTRY-281989 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Specialty testing: neurology – retire 06/30/2026PayerPolicy · HEALTHPARTNERS-CC-ENTRY-290172 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Specialty testing: nephrologyPayerPolicy · HEALTHPARTNERS-CC-ENTRY-232708 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Specialty testing: multisystem genetic conditions – retire 06/30/2026PayerPolicy · HEALTHPARTNERS-CC-ENTRY-290464 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Specialty testing: immunology and rheumatology – retire 06/30/2026PayerPolicy · HEALTHPARTNERS-CC-ENTRY-290147 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Specialty testing: immunology and rheumatologyPayerPolicy · HEALTHPARTNERS-CC-ENTRY-232491 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Specialty testing: endocrinology – retire 06/30/2026PayerPolicy · HEALTHPARTNERS-CC-ENTRY-290306 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Somatostatin analogues for acromegaly (Sandostatin LAR, Somatuline Depot, Signifor LAR, Somavert, Lanreotide)PayerPolicy · HEALTHPARTNERS-CC-AENTRY-046147 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Skilled nursing facility (SNF) - Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-AENTRY-046144 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Site of service – attended polysomnography for evaluation of obstructive sleep apnea (OSA)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-219236 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Sebelipase alfa (Kanuma)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-183256 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Satralizumab-mwge (Enspryng) and inebilizumab-cdon (Uplizna)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-231391 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Romosozumab-aqqg (Evenity)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-212858 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Rhinoplasty and septorhinoplastyPayerPolicy · HEALTHPARTNERS-CC-AENTRY-046127 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Residential – psychiatric residential treatment facility (PRTF)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-279614 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Residential - psychiatric residential treatment facility (PRTF) - Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-206014 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Residential - children’s treatment services - Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-AENTRY-045845 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Reproductive testing: prenatal screeningPayerPolicy · HEALTHPARTNERS-CC-ENTRY-232426 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Removal of benign and malignant skin lesionsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-288810 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Remestemcel-L-rknd (Ryoncil)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-286215 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Recent Food and Drug Administration (FDA) approved medications coverage policyPayerPolicy · HEALTHPARTNERS-CC-AENTRY-046122 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Radiofrequency ablative (RFA) denervation procedures for chronic facet-mediated neck, back and sacroiliac joint painPayerPolicy · HEALTHPARTNERS-CC-AENTRY-046316 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Prosthesis – lower limb – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-259151 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Prosthesis - upper limbPayerPolicy · HEALTHPARTNERS-CC-AENTRY-046198 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Prosthesis - lower limbPayerPolicy · HEALTHPARTNERS-CC-AENTRY-046114 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Prostaglandin intracameral implants: travoprost intracameral implant (iDose TR, Durysta)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-287103 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Preventive care servicesPayerPolicy · HEALTHPARTNERS-CC-AENTRY-046106 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Pozelimab-bbfg (Veopoz)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-270206 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Pompe disease enzyme replacement therapy: alglucosidase alfa (Lumizyme), avalglucosidase alfa-ngpt (Nexviazyme), cipaglucosidase alfa-atga (Pombiliti) - Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-187832 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Pompe disease enzyme replacement therapy: alglucosidase alfa (Lumizyme), avalglucosidase alfa-ngpt (Nexviazyme), cipaglucosidase alfa-atga (Pombiliti)PayerPolicy · HEALTHPARTNERS-CC-AENTRY-045970 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Personal care assistant (PCA) / Community First Services and Supports (CFSS) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-AENTRY-046092 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Percutaneous tibial nerve stimulation (PTNS) for overactive bladderPayerPolicy · HEALTHPARTNERS-CC-AENTRY-046089 | Criteria changed |
|---|
| May 14, 2026 | HealthPartners | Pegloticase (Krystexxa)PayerPolicy · HEALTHPARTNERS-CC-AENTRY-046270 | Criteria changed |
|---|